| Autor: |
Leal, Rodrigo Peñuelas, Labrandero Hoyos, Carolina, Grau Echevarría, Andrés, Martínez-Doménech, Alvaro, Casanova Esquembre, Andrés, Ninet, Violeta Zaragoza, Ferriols, Amparo Pérez, Carazo, Jose Luis Sánchez |
| Předmět: |
|
| Zdroj: |
Clinical & Experimental Dermatology; Sep2023, Vol. 48 Issue 9, p1060-1062, 3p, 2 Color Photographs |
| Abstrakt: |
The latter is an oral phosphodiesterase-4 inhibitor (PDE4i), approved in 2020 by the European Medicines Agency (EMA) for the treatment of BD-related aphthosis.[2] Roflumilast is another oral PDE4i administered once daily that has been approved by the EMA for chronic obstructive pulmonary disease since 2010. In recent years, BD has begun to be considered as an autoinflammatory disease.[1] Clinically, dermatological manifestations predominate, mainly in the form of genital aphthosis and oral aphthosis (OA), although acneiform lesions, erythema nodosum and skin ulcers may also be present. Dear Editor, Behçet disease (BD) is a multisystem vasculitis. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
